Thymus and autoimmunity

Alexander Marx 1, Yosuke Yamada 1,2, Katja Simon-Keller 1, Berthold Schalke 3, Nick Willcox 4, Philipp Ströbel 5, Cleo-Aron Weis 1

Received: 14 October 2020 / Accepted: 12 January 2021 / Published online: 3 February 2021
© The Author(s) 2021

Abstract
The thymus prevents autoimmune diseases through mechanisms that operate in the cortex and medulla, comprising positive and negative selection and the generation of regulatory T-cells (Tregs). Egress from the thymus through the perivascular space (PVS) to the blood is another possible checkpoint, as shown by some autoimmune/immunodeficiency syndromes. In polygenic autoimmune diseases, subtle thymic dysfunctions may compound genetic, hormonal and environmental cues. Here, we cover (a) tolerance-inducing cell types, whether thymic epithelial or tuft cells, or dendritic, B- or thymic myoid cells; (b) tolerance-inducing mechanisms and their failure in relation to thymic anatomic compartments, and with special emphasis on human monogenic and polygenic autoimmune diseases and the related thymic pathologies, if known; (c) polymorphisms and mutations of tolerance-related genes with an impact on positive selection (e.g. the gene encoding the thymoproteasome-specific subunit, PSMB11), promiscuous gene expression (e.g. AIRE, PRKDC, FEZF2, CHD4), Treg development (e.g. SATB1, FOXP3), T-cell migration (e.g. TAGAP) and egress from the thymus (e.g. MTS1, CORO1A); (d) myasthenia gravis as the prototypic outcome of an inflamed or disordered neoplastic ‘sick thymus’.

Keywords Thymus · Myasthenia gravis · Tuft cells · Myoid cells · AIRE · FEZF2

Introduction
The thymus generates responsive T-cells from immature precursors (together called ‘thymocytes’) as key players in a functional adaptive immune system. It also prevents human autoimmune diseases (HAIDs) through both negative

This article is a contribution to the special issue on: The thymus and autoimmunity - Guest Editor: Georg Holländer

1 Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
2 Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto 606-8507, Japan
3 Department of Neurology, Bezirkskrankenhaus, University of Regensburg, 93042 Regensburg, Germany
4 Neurosciences Group, Nuffield Department of Clinical Neurology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK
5 Institute of Pathology, University Medical Center Göttingen, University of Gottingen, 37075 Göttingen, Germany

selection (by which most autoreactive α/β-T-cells are deleted [1, 2]) and generation of FOXP3+ regulatory T-cells (Tregs) [3–6] that restrain those autoreactive T-cells that inevitably escape negative selection and seed the periphery [7, 8]. Thymic tolerogenic mechanisms require thymic epithelial cells (TECs), dendritic cells (DCs) and B-cells and involve the cortex, medulla and perivascular spaces (PVS) (Fig. 1). Monogenic HAIDs have been crucial to identifying key contributors to tolerance, e.g. the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED, alias autoimmune polyglandular syndrome type 1, APS1) due to autoimmune regulator (AIRE) mutations [9, 10], the immunodysregulation polyendocrinopathy and enteropathy X-linked (IPEX) syndrome resulting from FOXP3 mutations [11] and ‘leaky’ (subtotal) immunodeficiency syndromes due to primary T-cell or stromal cell developmental defects [12, 13]. Parallel studies in mouse models helped to elucidate underlying mechanisms and their non-redundancy [6, 14–16]. In many sporadic polygenic HAIDs, the role of the thymus is difficult to prove, since disorders in tolerogenesis are often subtle and need complementary genetic, epigenetic, hormonal or environmental cues [17]. ‘Primary’ inflammatory and neoplastic disorders of the thymus in myasthenia gravis (MG) have highlighted thymic abnormalities that correlate with autoimmunity in humans [18].
The thymic medulla and autoimmunity

AIRE expression in the thymic medulla

Identifying AIRE mutations as the cause of the APECED syndrome [9, 10] has deepened the understanding of negative selection. AIRE also supports the generation of antigen-specific natural Tregs in mice [15] and humans [19]. In humans, AIRE is expressed in the nuclei of rare mTECs mainly in the vicinity of Hassall corpuscles (Fig. 1). Since APECED thymic tissue is not available, AIRE’s function has been elucidated through mouse models, although they do not fully mirror the clinical features of human APECED [20–22].

AIRE and negative selection AIRE is a transcriptional modulator that is mainly expressed in MHCII high mTECs. Their development from AIRE−, MHCII low precursors requires RANK/RANKL and CD40/CD40L signalling that, in turn, depends on thymopoiesis [23–25]; when it is deficient, thymic AIRE expression is therefore also missing, as in some primary T-cell immunodeficiencies. In mTECs, AIRE is part of a multimeric complex including transcription factors, enhancers and DNA repair molecules [26] and drives the low-level ‘promiscuous gene expression’ (pGE) of more than 3000 tissue-restricted self-antigens (TRAs) [16], comprising about 40% of all TRAs expressed in the thymus [27]. Presentation of MHC-bound, thymoproteasome-processed TRA-peptides [28] by mTECs deletes any maturing thymocytes with high affinities for these complexes [14, 16] or diverts them into the Treg lineage [29]. By contrast, cleavage in autophagic vacuoles is needed for peptide loading onto MHCII molecules [30], and blocking autophagy in mice elicits autoimmune colitis and multi-organ inflammation [31].

To achieve pGE, AIRE is preferentially recruited to promoters with low levels of H3K4 methylation [32]. It also induces topoisomerase II-dependent double-strand breaks, the editing and splicing of RNA [26, 33, 34]; promotes the release of stalled RNA polymerase-II [35] and enhances the binding of super-enhancers to ‘orderly relaxed’ chromatin [36, 37]. Furthermore, AIRE-dependent RNAs are preferentially stabilised through the 3’ end processing complex that
AIRE is involved in the positive AIRE and Treg development directly through AIRE+ mTECs [15] or indirectly by their selection of a subset of self-antigen-specific Tregs, whether is less clear: it might even be linked to the maturation of induction, the relevance of AIRE expression in a few of each DCs [55]. While B-cells and DCs are important for tolerance may explain the gender bias of several autoimmune diseases [56], using different molecular transfer mechanisms for cell surface and cytosolic proteins [47]. It is unknown why some AIRE-dependent TRAs preferentially induce Treg development to TEC-derived TRAs [8, 45–47], especially any derived from AIRE-independent TRAs [48].

AIRE expression in cells other than mTECs: AIRE is also expressed at lower levels in minority subsets of (i) murine and human thymic B-cells [49–52], (ii) CCR7+ PDL1+CD127+ medullary thymic DCs [53, 54] and (iii) rare extrathymic DCs [55]. While B-cells and DCs are important for tolerance induction, the relevance of AIRE expression in a few of each is less clear: it might even be linked to the maturation of thymic and peripheral DCs [53].

AIRE and Treg development AIRE is involved in the positive selection of a subset of self-antigen-specific Tregs, whether directly through AIRE+ mTECs [15] or indirectly by their transfer of MHCI/TRA peptide complexes to AIRE+ DCs [56], using different molecular transfer mechanisms for cell surface and cytosolic proteins [47]. It is unknown why some AIRE-dependent TRAs preferentially induce Treg development [29, 57], whereas others induce deletion [58].

Human AIRE-related autoimmune features Patients with inactivating AIRE mutations develop APECED due to autoimmunity T- and B-cell responses that damage many organs, preferentially the adrenal cortex and parathyroid glands [20]. In contrast to AIRE-deficient mice [21], nearly all APECED patients show neutralizing autoantibodies to type 1 interferons and TH17 interleukins [59–61], and loss of TH17 and TH22 cells [62], which correlate with the characteristic mucocutaneous candidiasis, which is often the first sign of APECED [62, 63]. Their autoantibodies to TH17-directed cytokines interfere with macrophage activation, whereas others (e.g. against IL-22) reportedly protect against type 1 diabetes (T1D) [64]. APECED patients also variably share autoantibodies with other HAIDs, including cancer tissue antigens [65], suggesting a role of the thymus in anti-tumour immunity [66, 67].

AIRE polymorphisms have been associated with sporadic vitiligo [68] and rheumatoid arthritis (RA) [69] but not with other common autoimmune diseases such as T1D [70]. Mutations of genes that encode ‘AIRE partners’ (e.g. mutations of PRKDC [71]) can cause APECED-like syndromes.

Pathology The features of thymi in APECED patients are unknown. AIRE expression deficits in humans occur in thymomas (see below) and primary immunodeficiencies.

FEZF2 and CHD4 expression in mTECs
The second gene identified to drive TRA expression in the thymus is the transcription factor ‘forebrain expressed zinc finger 2’ (Fezf2) [72]. It is mainly expressed in the brain [73, 74], also close to Hassall corpuscles in the human thymus, and in a subset of mTECs, some being AIRE+ too [39] (Fig. 1). Fezf2 regulates the expression of about 400 TRAs that are distinct from those regulated by AIRE [34]. About 1000 TRAs are co-regulated by either Fezf2 and AIRE [34] or Fezf2 and Chd4 [39]. Transplantation of Fezf2−/− thymi into nude mice elicits organ infiltrates and autoantibodies that are different from those in AIRE−/− mice [14, 72].

Recently, chromodomain helicase DNA-binding protein 4 (Chd4) was identified as the first Fezf2-interacting protein [39]. It is a broadly expressed chromatin modulator that elicits histone modifications of its target genes distinct from those in AIRE-induced genes [39]. Chd4 and Fezf2 cooperatively regulate the expression of more than 25% of Fezf2-dependent genes by modifying the chromatin state around them, while Chd4’s co-regulation of 30% of AIRE-dependent genes [39] involves super-enhancers [34]. In mice, Chd4 induces the expression of a small set of unique genes [39].

Human FEZF2 and CHD4-related autoimmune features As yet, there is no genetic or pathologic evidence directly to incriminate FEZF2 or CHD4 in either sporadic HAIDs or syndromes analogous to APECED. However, some Fezf2-dependent TRAs identified in mice are autoantigens in humans, including aquaporin 8 (AQP8) in Sjögren syndrome [75] and transthyretin (TTR) in juvenile idiopathic arthritis (JIA) [76]. Some of the Chd4-(co-)regulated genes in mice encode human autoantigens, including TSHR, the key autoantigen in Graves’ disease [77, 78].

Other autoimmune risk polymorphisms involving mTECs
Some risk polymorphisms for sporadic HAIDs operate in the thymus, e.g. those in the AIRE-driven INS/insulin promoter that associate with insulin expression levels in the thymus rather than the pancreatic islets and, inversely, with the risk of developing T1D [79, 80] even among APECED patients [81]. Similarly, a polymorphism in the IRF8-binding site in the promoter of the AIRE-driven gene encoding the
acetylcholine receptor (AChR) α-subunit has been linked to reduced AChR expression in the thymus and the risk of very early–onset myasthenia gravis [82]. Analogous scenarios apply to Graves’ disease [77], autoimmune myocarditis [83] and central nervous system autoimmunity (see A. Handel, this fascicle).

**Hassall corpuscles, thymic tuft cells, thymic myoid cells and autoimmunity**

Like thymic tuft cells, the squamoid cells that constitute Hassall corpuscles (HCS) in the human medulla (Fig. 1) and inconspicuous aggregates in the murine thymus [84] are terminally differentiated mTECs [85–87]. Thymic myoid cells are rare skeletal muscle-like cells occurring close to HCs [88].

Hassall corpuscles arise from AIRE+ MHCII-high mTECs under the influence of thymocyte-dependent lymphotoxin signals [87]. Terminal mTEC differentiation is accompanied by downregulation of AIRE, MHCII and CD80/CD86 and upregulation, e.g. of KRT10, involucrin, desmogleins and serine protease inhibitor (SPINK5), characteristic of terminally mature cutaneous keratinocytes [34, 86]. Despite the downregulation of AIRE, squamoid mTECs still express many AIRE-dependent and independent TRAs before dying inside HCs [48]. HCs supposedly promote tolerance in two ways: through transfer of TRAs to nearby DCs for cross-presentation [34] and through secretion of thymic stromal lymphopoietin (TSLP) that induces CD80/CD86 [34] and through secretion of thymic keratinocytes [34, 86]. The TSLP pathway may not operate in mice, whose squamoid mTECs lack TSLP expression [85].

Thymic tuft cells (TTCs) in mice likely represent the rare microvillous mTECs [91]. They arise from AIRE+ and AIRE– mTECs [85, 86] and partially resemble the chemosensory tuft (‘brush’) cells that were first identified in mucosal tissues [92, 93] and meanwhile in many other organs [94]. Like other tuft cells but unlike other TECs, TTCs develop under the control of the transcription factor, POU2F3, and express many tuft cell markers, including IL-25, the protein kinase DCLK1, pro-inflammatory cyclooxygenases [95], proteins involved in acetylcholine metabolism (e.g. ChAT) and taste transduction (e.g. Trpm5); yet, they do not show pGE [85, 86]. On the other hand, TTCs specifically express MHCII and CD74 that are involved in antigen presentation; they also induce tolerance against IL-25 that is lost in TTC-deficient mice [86], though its breadth and mechanisms are currently unknown.

Thymic myoid cells (TMCs) are evolutionarily conserved, non-innervated mesenchymal cells that resemble myoblasts or myotubes [88] and occur in the normal medulla (i.e. near HCs, AIRE+ and FEZF2+ mTECs, POU2F3+ thymic tuft cells and thymic B, T and DCs). Their origins [96, 97] and kinship to mTECs with a ‘myoid phenotype’ [54] are unclear. In contrast to mTECs, TMCs express AChR in its native confirmation [98] that is exclusively recognised by MG patients’ autoantibodies: indeed, they are the only cells outside the muscle to express this key target autoantigen, as well as titin [99] and ryanodine receptors (RyRs) [100]. Since TMCs are MHCI- [98], they may contribute to tolerance through transfer of muscle self-antigens to DCs for cross-presentation to T-cells [18]. So may isolated AChR subunits or other muscle proteins that are also expressed by mTECs [54, 98, 101], suggesting that immune tolerance to skeletal muscle has been a high priority during evolution.

**Human autoimmune features related to HCs, TTCs and TMCs**

Impaired TEC/thymocyte crosstalk leads to lack of AIRE+ mTECs and of the HCs that they generate, possibly increasing risks of HAIDs: many primary T-cell immunodeficiency syndromes, e.g. hypomorphic defects of RAG-1, and some inborn errors of thymic stroma development result in lymphocyte-poor, AIRE– and HC-deficient thymic rudiments (‘thymic dysplasia’) and may associate with HAIDs (see R. Bachetta and F. Dhalla in this fascicle). So does trisomy 21, with three AIRE alleles, enlarged HCs and increased risks of T1D, but the mechanisms involved are controversial [102–104]. The decline of HC numbers during aging [105] results from a decline of haematopoietic and epithelial cell functions [106] and may contribute to the increased prevalence of some HAIDs in the elderly [107]. Thymic tuft cell deficiency has not been reported in humans. Combined deficiencies of TMCs, HCs and AIRE expression in thymomas are detailed below.

**Hematopoietic cells in the thymic medulla and autoimmunity**

Thymic dendritic cells are classified as CD8α±Sirpα± conventional DCs (cDC1s in mice and CD141+ cDCs in humans), CD8α±Sirpα± DCs (cDC2s, including a monocyte-derived CD14+ DC subset [108]) and plasmacytoid DCs (pDCs) [108–110]. cDC1s are generated intrathymically from immature precursors recruited to the thymus by mTEC-derived CCL21s [111], while other DCs are attracted from the periphery as mature cells [112, 113] by mTEC-derived chemokines, some of which require toll-like receptor 9 (TLR9)/MYD-88 signalling for production [108]. AIRE-dependent mTECs secrete XCL1 [114] that attracts cDCs and facilitates their acquisition of promiscuously expressed antigens from mTECs [45–47, 115], while pDCs essentially present peripheral antigens [113]. Antigen transfer from mTECs to DCs is key for the cross-presentation of promiscuously expressed antigens for negative selection [8, 45, 115] and the generation of Tregs [47, 114, 116]. Compared with mTECs and medullary
B-cells, DCs show the highest expression levels of HLA genes but low levels of TRA genes [50, 53]. Thymic B-cells occur in the medulla from foetal life onwards [117]. Their abundance increases with age. Thymic AIRE+ and AIRE− B-cells play a role in deletional tolerance: following activation through autoreactive T-cells and CD40 signalling, B-cells express AIRE together with a set of TRAs and present MHCII/TRA-peptide complexes, and so specifically delete the autoreactive T-cells that activated them [52, 118]. In humans, 5% of thymic B-cells express AIRE [49, 50, 119]. Since their set of AIRE-dependent TRAs is different from that in mTECs, thymic B-cells may delete T-cells with distinct self-reactive specificities [49, 50, 119] or help to divert them into the Treg lineage [120–122].

Regulatory T-cells A minority of developing CD4+ T cells with α/β-T-cell receptors (TCR) develops towards the Treg lineage if recognizing self-peptide/MHCII complexes with intermediate affinities [123]. Thus, the TCR repertoire of thymus-derived Tregs (Tregs) is skewed towards recognizing self-antigens compared with conventional CD4+ helper T-cells (TH-cells) [124]. Tregs constitute about 10% of all CD4+ T-cells, of which 80–90% are Tregs; peripheral Tregs (pTregs) arise from mature, conventional CD4+ T-cells [125]. The development of Tregs starts in the cortex: in the presence of TCR and IL-2/STAT3 signalling, the transcription factor, SATB1, binds to closed DNA regions in cortical CD4+CD8+ thymocytes to initiate chromatin opening. A defect at this level elicits Treg deficiency and autoimmunity [126]. Subsequently, CD4+CD8− single positive thymocytes develop in the medulla through further epigenetic modifications, establishment of the ‘Treg-specific demethylated region, TSDR’ [127] and binding of transcription factors (e.g. RUNX1, CBFB, ETS1, FOXO1 and 3) that drive expression of Treg-specific demethylated region, TSDR [127] and binding of transcription factors (e.g. RUNX1, CBFB, ETS1, FOXO1 and 3) that drive expression of CD25, FOXP3, CTLA4 and other ‘Treg signature genes’ [128]. Cues from Hassall corpuscle-instructed medullary DCs [89] and AIRE+ mTECs [15, 19] in the presence of MHCII, CD80/86 and IL-2 [90] control the abundance, antigen-specificity and suppressive competence of these Tregs. Once expressed, FOXP3 maintains survival and function of Tregs through driving target gene expression (e.g. of CD25/IL2RA and CTLA4) or suppression of pro-inflammatory IL2 and IFNG) [123]. Recently, two developmental pathways leading to Tregs with distinct target specificities were described [129] and may be present in the human thymus [54].

Human autoimmune features related to hematopoietic cells Thymic DC numbers do not change much during ageing [130], but proinflammatory genes (e.g. LIF, IL6) are increasingly expressed and may contribute to involution [131, 132], though with no proven link to HAIIDs.

In B-cells, the declining transcription with age of AIRE and rare TRA genes, including TTN (encoding the muscle protein, titin), has been linked to the commoner occurrence of some HAIIDs including MG in the elderly [49, 107]. Severe defects of Tregs occur in monogenic autoimmune diseases. For example, IPEX syndrome (analogous to murine scurfy syndrome [3]) results from different mutations across the FOXP3 gene [133], showing that Tregs are indispensable to prevent T1D (even perinatally), inflammatory bowel disease and allergies, although the clinical variability of IPEX correlates poorly with the type of FOXP3 mutation [134]. Other mutations in CD25, CTLA4, LRBA, BACH2 and STAT3 cause ‘IPEX-like syndromes’ due to Treg dysfunction. Differences in their expression, e.g. in follicular TH- and B-cells, may contribute to clinical differences between these ‘Tregopathies’ [135] (see R. Bacchetta in this fascicle). In addition, genetic variants in Treg-related loci associate with some common sporadic autoimmune diseases [128, 136].

Pathology The thymus in an IPEX patient showed dysplasia, i.e. lack of lymphoid cells and Hassall corpuscles [137]. These changes are likely secondary, resembling those in scurfy mice, where severe thymic atrophy likely results from the cytokine storm and lymphoproliferation that develop in the absence of Tregs [138].

The thymic cortex and autoimmunity The thymic cortex provides the microenvironment for positive selection of conventional T-cells and early Tregs. Thus, its cTECs generate distinctive self-peptides via a unique set of proteases: (a) to select CD8+ thymocytes, cytosolic peptides are generated for presentation on MHCII molecules by the cortex-restricted ‘thymoproteasome’, with its unique Beta5t subunit (encoded by PSMB11) [28]; (b) to select CD4+ thymocytes, MHCII molecules in cTECs are loaded inside LAMP2+ endosomes with various endogenous self-peptides generated using cathepsin L and the thymus-specific serine protease, TSSP (encoded by CTLS and PRSSI6, respectively) [139]. Autophagy in cTECs is one source of such MHCII:peptide complexes [30]: they also owe their persistence on the cTEC surface to CD83-dependent blockade of MACH-8-mediated trafficking there [140, 141]. This positive selection clearly depends on some crucial survival signals for nascent T-cells delivered via their TCRs, available co-receptors and downstream molecules (such as the tyrosine kinase, ZAP70) that transmit TCR signals [142–144]. Once positively selected, thymocytes upregulate chemokine receptors (e.g. CCR7) and must migrate to the medulla along chemotactic gradients [145, 146] for proper establishment of central tolerance [147].
Human autoimmune features related to thymic cortical dysfunction

Homozygosity for the rs54457782 SNP of PSMB11 has been associated with altered B5t function of the protein in cTECs and an elevated risk of Sjögren syndrome in one study [148]. Deletion of Prss16 in cTECs clearly protects NOD mice against T1D, presumably by affecting processing of pancreatic islet cell TRAs [149]. A role of PRSSI6 in HAIIDs has not been proven.

Polymorphisms of the C-type lectin CLEC16A gene show associations with T1D, multiple sclerosis (MS), systemic lupus (SLE), celiac disease, RA and JIA. Mouse studies implicate CLECA16’s impact on autophagy in cTECs or mTECs and thus on the repertoire of MHCII/self-peptide complexes for CD4+ T-cell selection [150].

In a similar scenario, ‘autoimmunizing positive selection’ (complemented by defective negative selection) might be operative in thymomas (see below), and in patients with ZAP70 mutations: while inactivating mutations of ZAP70 cause severe immunodeficiency, hypomorphic mutations lead to positive selection of autoreactive thymocytes [142]. Since attenuated ZAP70 signalling also attenuates negative selection and selection of Tregs, autoimmunity arises [151], leading to bullos pemphigoid, colitis and proteinuria in patients [152].

Nucleotide variants of TAGAP that encode a thymocyte GAP protein are associated with various HAIIDs, likely reflecting attenuated thymocyte migration from the cortex to the medulla [44].

Finally, associations of SNPs of SATB1 with colitis, psoriasis and MS have been linked to SATB1’s role in Treg development in the thymic cortex [126].

Pathology Expansion of the thymic cortex at the near-total expense of medullary regions is typical of thymomas (see below). Conversely, secondary cortical atrophy can result from the chronic re-entry of activated peripheral T-cells into the thymus in HAIIDs [153]. Cortical atrophy as a facet of thymic involution during aging is thought to increase the risk of HAIIDs [154].

PVS and autoimmunity

The third thymic compartment with relevance for autoimmunity is the epithelial-free perivascular space (PVS) (Fig. 1). It surrounds vessels that enter the thymus through the septa between cortical lobules up to the corticomediullary junction (CMJ) [155]. The PVS extends between the basal membranes of the outermost epithelial cells of thymic lobes to those of the intrathymic vessels. Barely visible in infants, these PVS enlarge with age [156]. At the CMJ, they are the entry sites for both immature lymphoid progenitors and recirculating T-, B- and dendritic cells from the blood and for exit for mature T-cells to the blood [145, 157, 158]. Furthermore, they are niches for B-cells and plasma cells spontaneously secreting protective antibodies that also prevent tolerance to viruses in healthy subjects [159], as in mice [160], or secrete pathogenic antibodies in early-onset myasthenia gravis (EOMG; see below).

Successfully selected CD69low nascent T-cells emigrate from the medulla to the PVS to the blood. That depends partly on cytokines, chemokines and integrins, also on (a) the sphingosine-1-phosphate (S1P) gradient between the S1Plow medulla and the S1Phigh blood [43], the balance between S1P-production by pericytes in the PVS and degradation by stromal cells (mostly DCs) in the medulla in mice [157, 161–164] and humans [165], and (b) the corresponding upregulation of S1P receptors (S1PR1) on the nascent T-cells; (c) signals from endothelial cells to pre-emigrant T-cells [166], and T-cell intrinsic factors like the protein kinase MTS1 (a member of the Hippo pathway) and the actin regulator, Coronin-1A (encoded by CORO1A) that regulate T-cell polarisation, adhesion and migration [157].

B-cells in PVS accumulate progressively with age and switch from a mainly IgM+ IgD+ CD27− naive phenotype in infants to a class-switched IgG1/IgG3/IgA+ CD27+ memory phenotype in adults [159].

Human autoimmune diseases related to T-cell migration and the PVS

Defects of thymocyte adhesion, migration and egress from the thymus are typically associated with a combined (T-/B-cell) immunodeficiency, as exemplified by mutations of MST1 [167–169] and CORO1A [163]. Poor adhesion and migration that compromise interactions between thymocytes and antigen-presenting cells attenuate positive and negative selection and the development and function of Tregs [43, 169, 170]. In MST1 mutant thymi, some T-cells typically escape to the periphery, where rarely oligoclonal or even monoclonal lymphoproliferations, organ infiltrates and autoantibody-mediated cytopenias develop [168, 171]. In CORO1A mutations, the egress defect is generally so severe that autoimmunity is generally prevented.

Pathology Thymi with defects in egress due to mutations of MST1 and CORO1A usually retain their corticomedullary architecture [163]. The generally mild defect in MST1 mutations shifts the balance towards a higher proportion of mature thymocytes, while the massive block to egress in CORO1A mutated thymi leads to ‘giant PVS’ with accumulations of mature T-cells [172].

Autoimmune myasthenia gravis—the inflamed and neoplastic thymus

Myasthenia gravis (MG) is a CD4+ T-cell-dependent HAIID, where autoantibodies interfere with neuromuscular transmission, causing muscle weakness. Autoantibodies in 80% bind
to the AChR [173]. This ‘AChR-MG group’ comprises EOMG (onset before age ~50), late-onset MG (LOMG; onset age >50) and thymoma-associated MG (TAMG) that show inflammatory, atrophic and neoplastic thymic alterations, respectively, with distinct clinical and genetic associations (Table 1). Here, we focus an EOMG and TAMG, since patients with LOMG appear heterogeneous, pathogenesis is largely unclear [175, 180, 181], and MG types due to other autoantibodies have an uncertain thymic phenotype [182–184].

**Thymic inflammation and immunopathogenesis of early-onset MG**

The hallmark of EOMG is thymic follicular hyperplasia (TFH), i.e. ectopic lymphoid follicles in PVSs merging with the thymic medulla [185] (Fig. 2). TFH shows germinal centres and increased numbers of B-cells and plasma cells and correlates with intrathymic production of heterogeneous IgG autoantibodies with high affinities for native AChR. Female gender and the HLA-DR3 B8 A1 haplotype are strong risk factors [186], B8 appearing the strongest [177], though roles of other loci are less clear (Table 1). EOMG is highly heritable [179] and commonly associated with other AIDs, predominantly thyroiditis, SLE and RA [184, 186]. The triggers of TFH are unknown [187]. A type I interferon signature in the EOMG thymus [191] by terminal plasma cells [192]; (2) in many patients, they preferentially recognise foetal AChRs [193] that are almost exclusively expressed on thymic myoid cells (TMCs); (3) TMCs are attacked by autoantibodies and complement in EOMG [182, 190] and closely associate with DCs that supposedly cross-present TMC-derived AChR-peptides to autoreactive T-cells for subsequent stimulation of autoreactive B-cells [194]; (4) lymphoid follicles disrupt the normally continuous basal membrane and epithelial cell layer around PVS, displacing TMCs from the tolerogenic medullary parenchyma into the inflamed vicinity of lymphoid follicles, many of which harbour AChR-autoreactive B-lineage cells in germinal centres [192, 195]; (5) in EOMG, mTECs that express unfolded AChR subunits [101] are attacked by complement and anti-epithelial autoantibodies of unknown specificity [196, 197] and over-express CXCL13 that recruits peripheral B-cells to the thymus [198]. Together with the beneficial effect of thymectomy [199], these findings support the ‘intrathymic pathogenesis concept’ of EOMG [189, 200]. Based on these observations, the finding of AChR-autoreactive, CD4+ effector T-cells in the repertoire of almost everybody [201, 202] and the fact that mature human T-cells recirculate to the thymus [203] currently favour a 2-step intrathymic pathogenesis model of EOMG [190] (Fig. 3):

- **Step 1:** AChR-reactive T-cells are primed (for unknown reasons) by mTECs that express MHC/AChR-peptide complexes, and then elicit low-affinity antibodies against linear AChR epitopes.
- **Step 2:** These ‘early antibodies’ attack AChR+ TMCs, activate complement and cause the release of AChR/immune complexes that, in turn, activate DCs to initiate ectopic follicle and germinal centre formation and focus the autoantibody response onto AChR rather than other muscle targets [190].

It is unknown whether follicles develop primarily near TMCs in the medulla and subsequently in B-cell niches in PVS [159] or vice versa. In either case, a very similar scenario has since been proposed for the development of thymic B-cell follicles in type 1 diabetes-prone NOD mice, including the attack of associated MG (TAMG) [82, 174–180]. Onset-ages may be subject to revision. EOMG and LOMG may prove to overlap, and the cut-off age(s) to differ between the sexes.

| MG type | Autoantigen targets | Onset-age (years) | M:F ratio | Genetic risk factors in Caucasians | Thymic pathology | AIRE* mTECs | Myoid cells |
|---------|---------------------|-------------------|-----------|-----------------------------------|-----------------|------------|------------|
| EOMG    | AChR                | <50–60            | 1:3       | MHC class I >II* (CHRNA1*) PTPN22 (CTLA4low) (TNIP1) | Ectopic germinal centres | Normal number | Normal number |
| LOMG    | AChR + titin cytokines RYR1/2 | >50–60 | 2:1 | MHC class II >I* TNFSR11A (PTPN22) (CTLA4low) | Atrophy | Reduced | Reduced |
| TAMG    | AChR + titin cytokines RYR1/2 | Any (median age ~50) | 1:1 | None established (CTLA4high) | Thymic epithelial neoplasm | Absent | Absent |

*CHRNA1 AChR α-subunit gene [82], PTPN22 protein tyrosine phosphatase, non-receptor-type, 22, CTLA4 cytotoxic T lymphocyte-associated 4; the unique CTLA4 high-expresser risk genotype in TAMG suggests a role of CTLA4 in central tolerance failure [176], TNIP1 TNF receptor superfamily, member 11A (RANK), RYR1/2 ryanodine receptors 1 and 2

* a Associations awaiting confirmation [174–177, 179, 180] are given in brackets; the HLA-DQA1*05:01 gene is predisposing in EOMG and protective in LOMG [177, 180]

* b Cytokines (type I interferons; IL12)
anti-epithelial autoantibodies on autoantigen (insulin)-expressing mTECs, activation of autoreactive T-cells and accumulation of B-cells [204].

TFH responses might be self-perpetuating in EOMG if (i) AChR persists on TMCs that are damaged by complement but do not disappear [205]; (ii) Tregs are functionally compromised [206, 207]; and (iii) TLR-expressing antigen-presenting cells are abnormally active [208]. Finally, autoreactive T- and B-cells spread to the periphery [209], where, hypothetically, the flow of skeletal muscle-derived AChR/antibody-complexes to regional lymph nodes and functionally impaired Tregs perpetuate EOMG even after thymectomy [184, 199].

**Thymoma and the immunopathogenesis of TAMG**

Thymomas are thymic epithelial tumours with variably mixed cortical and medullary differentiation accompanied by thymopoiesis in >90% of patients [210, 211]. TAMG is the single most common thymoma-associated HAID (30–40%), while others (e.g. thyroiditis, RA, and especially SLE, pure red cell aplasia (PRCA), hypogammaglobulinaemia or other bone marrow failures are individually less common (each 1–5%) but, together with TAMG, amount to over 50% thymoma-associated HAIDs [18]. Most of the HAIDs are CD4+ T-cell-dependent, autoantibody-mediated (e.g. TAMG), while cytotoxicity may be operative in others (e.g. in PRCA) [212, 213]. Unlike in EOMG, >80% of patients with thymomas have autoantibodies to non-AChR skeletal muscle antigens (titin and RYRs) and others that neutralise such cytokines as type I interferons (~70% [22, 61, 62] and IL-12) (Table 1). Those against the muscle have been attributed to the lack of thymic myoid cells (TMCs) in thymomas [18] and/or expression of AChR, titin and RYR epitopes in neoplastic thymic epithelial cells [100, 214].

The autoantibodies against type I interferons (all 12 subtypes [190]) are among several striking parallels with >90% of APECED patients: others include the chronic mucocutaneous candidiasis (CMC) that is often the first sign of APECED, also occurs in ~3% of thymoma patients and has an autoimmune basis in both—i.e. autoantibodies against IL-17s and/or IL-22 and loss of the cytokine-producing cells [62]. The apparent absence of AIRE in most thymomas [215] renders these tumours the most practical alternative for studying AIRE-deficient thymopoiesis in humans [22, 216]. The differences between these syndromes include the rarity in APECED patients of MG or of almost any neurological disorder or auto-antibody [22]; they may partly reflect the contrasting effects of AIRE mutations present since conception in APECED versus
the focal acquisition of a neoplastic AIRE-deficient clone of thymic epithelial cells in adult thymoma patients who already have an established normal peripheral immune repertoire. The clinical variability among thymoma patients has given clues to the pathogenesis of TAMG [18]:

1. Strong gender and genetic risk factors apparently contribute little to its development (Table 1), suggesting that the tumour is its main etiological factor.

2. Strongly thymopoietic thymomas confer greater TAMG-susceptibility than those with poor thymopoiesis; thymic carcinomas without thymopoiesis almost never develop MG [214].

3. Thymomas that generate naïve CD4+ T-cells that then contribute to the peripheral TH-cell repertoire associate more strongly with the TAMG than others that fail to ‘export’ single positive CD4+ progeny [212, 217]. Also, TAMG(+) thymomas appear enriched for AChR-reactive thyocytes [218]. The reason for this dichotomy at the level of CD4+ T-cells is only partly understood [219]. By contrast, export of CD8+ T-cells from thymomas is maintained irrespective of MG status [217].

4. In sharp contrast with the findings in EOMG thymi [191], conformation-specific autoantibodies to AChRs are not produced by cells from thymomas [100, 220, 221]. However, other autoantibodies against IFN-α or IL-12 are produced by thymoma plasma cells; moreover, their titres usually rise sharply when thymomas recur, suggesting immunisation against linear epitopes within the tumours [221].

5. With rare exceptions [22, 222], levels of mRNA encoding the AChR α-subunit are higher in TAMG(+) thymomas than in TAMG(-) thymomas, hinting at immunisation there rather than tolerance induction [22, 100, 214, 221], unlike in the normal thymus [82]. Similarly, IFN-α are present in thymomas [190], obviously AIRE-independent and clearly fail to tolerate there—again contravening standard dogma [14]. AIRE reportedly has additional tolerogenic actions [223]. If so, their loss may create aberrant thymic environments where it becomes ‘dangerous’ to express autoantigens. Wolff et al. [22] therefore proposed two parallel mechanisms in APECED thymi: in one, T-cells are actively auto-immunised, exported and go onto attack early, especially causing the unusual TH17 cell, parathyroid and adrenocortical failures, which mostly appear by ages 5–10 (in ~90 to ~70% of patients); in another scenario, T-cells

---

**Fig. 3** Two-step intrathymic pathogenetic model of early-onset myasthenia gravis. Step 1: On re-entry of acetylcholine receptor (AChR)-reactive T-cells from the blood to the thymus, the T-cells (activated by unknown triggers) get ‘primed’ by medullary thymic epithelial cells (mTECs) expressing MHC/AChR-peptide complexes. The primed T-cells activate thymic B-cells to produce low-affinity anti-AChR antibodies. Step 2: These autoantibodies bind to thymic myoid cells (TMCs) expressing native AChRs, activate complement and induce the release of AChR/antibody complexes from TMC for processing by nearby dendritic cells (DCs) that bind to follicular dendritic cells (FDCs). The germinal centre (GC) reaction finally results in plasma cells producing high-affinity anti-AChR autoantibodies. It is unknown whether lymphoid follicles arise primarily in the PVS (as shown on the left and in Fig. 1d) or in the medulla, and why AChR-reactive T-cells occur very commonly in the ‘physiological’ T-cell repertoire of healthy humans.
simply fail to get tolerised, e.g. versus insulin, which happens randomly, much later and less frequently.

The following abnormalities in thymomas could, in theory, contribute to the development of TAMG, but surprisingly are also common in TAMG(−) thymomas \[18, 210, 211, 215, 224–226\]: the frequently reduced expression of MHCII antigens on TECs; the common MHC haploinsufficiency of TECs due to loss of 6p21; the reduced expression of proteases in cTECs (e.g. PRSS16); the reduced size of medullary compared with cortical areas; the lack of AIRE⁺ mTECs and of Hassall corpuscles; the defective generation of FOXP3⁺ Tregs in thymomas; the paucity of B-cells and TMCs (Fig. 4).

Together, the findings have suggested a 4-step pathogenetic model for most thymomas that show thymopoiesis and express AChR/Titin epitopes:

1. Biased positive selection of developing specific TH-cells by neoplastic linear AChR/titin peptide-overexpressing TECs with cortical features expressing reduced levels of some HLA variants [211, 214, 224]
2. These self-reactive TH-cells survive or are even pre-primed \textit{in situ} by their target autoantigens, partly because of the absence of AIRE⁺ mTECs and Tregs [190], also because of combined defects of medullary functions (including lack of myoid cell-derived AChRs and titin for tolerogenic cross-presentation by APCs)
3. Autoreactive mature TH-cells pass the bottleneck to terminal maturation [217], and escape apoptosis in thymomas [219], exit to the blood and ‘infiltrate’ the existing tolerant T-cell repertoire with thymoma-derived autoreactive T-cells [212, 218]
4. In the periphery [209], including the remnant thymus [221], these escaping autoreactive TH-cells stimulate B-cells to generate autoantibodies against native AChRs after appropriate stimulation [217]. Once initiated, skeletal muscle-derived AChR/autoantibody complexes presented in regional lymph nodes perpetuate TAMG even after thymoma removal [227].

For the rare thymomas without thymopoiesis and AChR/Titin expression, alternative pathogenetic models may apply [18].

Finally, one should not forget that thymomas are malignant tumours that often require oncological interventions. Due to their propensity to ‘poison’ the immune system with potentially autoreactive CD8⁺ and CD4⁺ T cells [217], thymomas are exceptionally risky targets for immune checkpoint inhibitors, since they can unleash severe if not fatal autoreactivities particularly focused on skeletal and cardiac muscle [228].

**Fig. 4** Typical abnormalities of a thymoma with extensive thymopoiesis. \(\text{a}\) Conventional hematoxylin-eosin stain with predominant (dark) cortical areas and tiny (light staining) medullary regions. \(\text{b}\) TdT stain highlights extensive positively stained cortical areas (C) and small, unstained ‘medullary island’ (MI). \(\text{c}\) Absence of B-cells throughout the tumour (PAX5 stain). Note absence of Hassall corpuscles (due to absence of AIRE expression, not shown). Immunoperoxidase

**Conclusion**

Thymic tolerance-inducing mechanisms and their failure are extremely complex and have been difficult to study, particularly in humans, in whom autoimmune syndromes have
crucially spotlighted relevant genes and their actions. Novel single cell and spatial transcriptomic approaches, in conjunction with multiplex imaging techniques, have the potential to open new perspectives when applied to normal and diseased human thymus and appropriate mouse models.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Kaplan JW, Roehe N, Marrack P (1987) T cell tolerance by clonal elimination in the thymus. Cell 49(2):273–280. https://doi.org/10.1016/0092-8674(87)90568-x
2. Kisielow P, Teh HS, Blüthmann H, von Boehmer H (1988) Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 335(6192):730–733. https://doi.org/10.1038/335730a0
3. Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JG, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27(1):68–73. https://doi.org/10.1038/38784
4. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science (New York, NY) 298(5597):1395–1399. https://doi.org/10.1126/science.1075958
5. Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmrich J, Skee LK, Rolink A, Klein L (2007) Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by AIRE+ medullary thymic epithelial cells. Nat Immunol 8(4):351–358. https://doi.org/10.1038/nii1444
6. Derbinski J, Schulte A, Kiyevsky B, Klein L (2001) Promiscuous activation of CD4+CD25+ FOXP3(+) precursors and impaired activated population. J Immunol (Baltimore, Md : 1950) 167(8):3880–3889. https://doi.org/10.1172/jci23087
7. Sudres M, Verdier J, Truffault F, Le Panse R, Berrih-Aknin S (2018) Pathophysiological mechanisms of autoimmunity. Ann N Y Acad Sci 1413(1):59–68. https://doi.org/10.1111/nyas.13560
8. Marx A, Porubsky S, Belharzazem D, Saruhan-Direskeneli G, Schalke B, Strobel P, Weis CA (2015) Thyroma related myasthenia gravis in humans and potential animal models. Exp Neurol 270:55–65. https://doi.org/10.1016/j.expneurol.2015.02.010
9. Laks SS, Laurinhol T-T, Rossi LH, Lehtoviita A, Sairanen H, Perheentupa J, Kekäläinen E, Arstila TP (2010) Regulatory T cell defect in APECED patients is associated with loss of naive FOXP3(+) precursors and impaired activated population. J Autoimmun 35(4):351–357. https://doi.org/10.1016/j.jaut.2010.07.008
10. Husebye ES, Perheentupa J, Rauteamaa R, Kämpe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 266(5):514–529. https://doi.org/10.1111/j.1365-2699.2009.02990.x
11. Pöntynen N, Miettinen A, Arstila TP, Kämpe O, Alimohammadi M, Vaarala O, Peltola N, Ulmanen I (2006) AIRE deficient mice do not develop the same profile of tissue-specific autoantibodies as APECED patients. J Autoimmun 27(2):96–104. https://doi.org/10.1016/j.jaut.2006.06.001
12. Wolff AS, Kamer J, Oweli F, Ofstedal BE, Gilhus NE, Erichsen MM, Kämpe O, Meager A, Peterson P, Kisand K, Willcox N, Husebye ES (2014) Clinical and serological parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors. J Immunol (Baltimore, Md : 1950) 193(8):3880–3890. https://doi.org/10.4049/jimmunol.1401068
13. Akiyama T, Shimo Y, Yanai H, Qin J, Ohshima D, Maruyama Y, Asaumi Y, Kitazawa J, Takayanagi H, Penninger JM, Matsumoto...
M, Nitta T, Takahama Y, Inoue J (2008) The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29(3):423–437. https://doi.org/10.1016/j.immuni.2008.06.015

24. Hikosaka Y, Nitta T, Ohigashi I, Yano K, Ishimaru N, Hayashi Y, Matsumoto M, Matsuoi K, Penninger JM, Takayanagi H, Yokota Y, Yamada H, Yoshikai Y, Inoue J, Akiyama T, Takahama Y (2008) The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity 29(3):438–450. https://doi.org/10.1016/j.immuni.2008.06.018

25. Rossi SW, Kim MY, Leibbrandt A, Parnell SM, Jenkinson WE, Glanville SH, McConnell FM, Scott HS, Penninger JM, Jenkinson EJ, Lane PJ, Anderson G (2007) RANK signals from CD4(+) regulatory inducer cells regulate development of AIRE-expressing epithelial cells in the thymic medulla. J Exp Med 204(6):1267–1272. https://doi.org/10.1084/jem.20062497

26. Abramson J, Giraud M, Benoist C, Mathis D (2010) AIRE’s partners in the molecular control of immunological tolerance. Cell 140(1):123–135. https://doi.org/10.1016/j.cell.2009.12.030

27. St-Pierre C, Trofimov A, Brochu S, Lemieux S, Perreault C (2007) Thymic epithelial cell heterogeneity: TEC by TEC. Nat Rev Immunol 7(8):540. https://doi.org/10.1038/nri2188

28. Murata S, Sasaki K, Kishimoto T, Niwa S, Hayashi H, Takahama Y, Tanaka K (2007) Regulation of CD8(+) T cell development by thymus-specific proteasomes. Science (New York, NY) 316(5829):1349–1353. https://doi.org/10.1126/science.1141915

29. Malchow S, Leventhal DS, Lee V, Nishi S, Socci ND, Savage PA (2016) AIRE enforces immune tolerance by directing autoreactive T cells into the regulatory T cell lineage. Immunity 44(5):1102–1113. https://doi.org/10.1016/j.immuni.2016.02.009

30. Nedjic J, Aichinger M, Emmerich J, Mizushima N, Klein L (2008) Autophagy in thymic epithelial shapes the T-cell repertoire and is essential for tolerance. Nature 455(7211):396–400. https://doi.org/10.1038/nature07208

31. Aichinger M, Wu C, Nedjic J, Klein L (2013) Macropathology substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med 210(2):287–300. https://doi.org/10.1084/jem.20122149

32. Peterson P, Org T, Rebane A (2008) Transcriptional regulation by AIRE: molecular mechanisms of central tolerance. Nat Rev Immunol 8(12):948–957. https://doi.org/10.1038/nri2450

33. Danan-Gotthol M, Guyon C, Giraud M, Levanon EY, Abramson J (2016) Extensive RNA editing and splicing increase immune self-representation diversity in medullary thymic epithelial cells. Genome Biol 17(1):219. https://doi.org/10.1186/s13059-016-1079-9

34. Kadouri N, Nevo S, Goldfarb Y, Abramson J (2020) Thymic epithelial cell heterogeneity: TEC by TEC. Nat Rev Immunol 20(4):239–253. https://doi.org/10.1038/s41577-019-02238-0

35. Giraud M, Yoshida H, Abramson J, Rahl PB, Youlin RA, Mathis D, Benoist C (2012) AIRE unleashes stalled RNA polymerase to induce ectopic gene expression in thymic epithelial cells. Proc Natl Acad Sci U S A 109(2):535–540. https://doi.org/10.1073/pnas.1119351109

36. Bansal K, Yoshida H, Benoist C, Mathis D (2017) The transcriptional regulator AIRE binds to and activates super-enhancers. Nat Immunol 18(3):263–273. https://doi.org/10.1038/ni.3675

37. Pinto S, Michel C, Schmidt-Glene-Winkel H, Harder N, Rohr K, Wild S, Brors B, Kyewski B (2013) Overlapping gene coexpression patterns in human medullary thymic epithelial cells generate self-antigen diversity. Proc Natl Acad Sci U S A 110(37):E3497–E3505. https://doi.org/10.1073/pnas.1308311110

38. Guyon C, Jmari N, Padonou F, Li YC, Ucar O, Fujikado N, Couplier F, Blanchet C, Root DE, Giraud M (2020) AIRE-dependent genes undergo Cpt1-mediated 3’UTR shortening associated with higher transcript stability in the thymus. eLife 9:e52985. https://doi.org/10.7554/eLife.52985

39. Tomofuji Y, Takaba H, Suzuki HI, Benlaribi R, Martinez CDP, Abe Y, Morishita Y, Okamura T, Taguchi A, Kodama T, Takayanagi H (2020) Cd44 choreographs self-antigen expression for central immune tolerance. Nat Immunol 21(8):892–901. https://doi.org/10.1038/s41551-020-0717-2

40. Berrih-Aknin S, Panse RL, Dragan N (2018) AIRE: a missing link to explain female susceptibility to autoimmune diseases. Ann N Y Acad Sci 1412(1):21–32. https://doi.org/10.1111/nyas.13529

41. Cloosen S, Arnold J, Thio M, Bos GM, Kyewski B, Gemerard WT (2007) Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res 67(8):3919–3926. https://doi.org/10.1158/0008-5472.can-06-2112

42. Derbinski J, Pinto S, Rösch S, Hexel K, Kyewski B (2008) Promiscuous gene expression patterns in single medullary thymic epithelial cells argue for a stochastic mechanism. Proc Natl Acad Sci U S A 105(2):657–662. https://doi.org/10.1073/pnas.0707486105

43. Duke-Cohan JS, Ishikawa Y, Yoshizawa A, Choi YI, Lee CN, Acuto O, Kissler S, Reinherz EL (2018) Regulation of thymocyte trafficking by Tagap, a GAP domain protein linked to human autoimmune disease. Sci Signal 11(534):eaan8799. https://doi.org/10.1126/scisignal.aan8799

44. Koble C, Kyewski B (2009) The thymic medulla: a unique microenvironment for intercellular self-antigen transfer. J Exp Med 206(7):1505–1513. https://doi.org/10.1084/jem.20082449

45. Hubert FX, Kinkel SA, Davey GM, Phipson B, Mueller SN, Liston A, Proietto AI, Cannon PZ, Forehan S, Smyth GK, Wu L, Goodnow CC, Carbone FR, Scott HS, Heath WR (2011) AIRE regulates the transfer of antigen from mTECs to dendritic cells for induction of thymic tolerance. Blood 118(9):2462–2472. https://doi.org/10.1182/blood-2010-06-286393

46. Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, Diferrero JF, Hsieh CS (2018) Transfer of cell-surface antigens by scavenger receptor CD36 promotes thymic regulatory T cell receptor repertoire development and allo-tolerance. Immunology 48(6):1271. https://doi.org/10.1016/j.immuni.2018.05.011

47. Michel C, Miller CN, Küchler R, Brors B, Anderson MS, Kyewski B, Pinto S (2017) Revisiting the road map of medullary thymic epithelial cell differentiation. J Immunol (Baltimore, Md : 1950) 195(10):5388–5393. https://doi.org/10.4049/jimmunol.1500558

48. E3497. https://doi.org/10.1073/pnas.1308311110

49. E3505. https://doi.org/10.7554/eLife.52985

50. E3507. https://doi.org/10.1038/s41551-020-0717-2

51. E3509. https://doi.org/10.1038/s41551-020-0717-2
antigens for T cell negative selection. Proc Natl Acad Sci U S A 110(42):17011–17016. https://doi.org/10.1073/pnas.1313001110

52. Yamano T, Nedjic J, Hinterberger M, Steiner M, Koser S, Pinto S, Gerdes N, Lutgens E, Ishimaru N, Busslinger M, Brors B, Kyewski B, Klein L (2015) Thymic B cells are licensed to present self antigens for central T cell tolerance induction. Immunity 42(6):1048–1061. https://doi.org/10.1016/j.immuni.2015.05.013

53. Fergusson JR, Morgan MD, Bruchard M, Huietma L, Heesters BA, van Unen V, van Hamburg JP, van der Wel NN, Picavet D, Koning F, Tas SW, Anderson MS, Marioni JC, Hollander GA, Spits H (2018) Maturing human CD127+-CCR7+-PDL1+- dendritic cells express AIRE in the absence of tissue restricted antigens. Front Immunol 9:2902. https://doi.org/10.3389/fimmu.2018.02902

54. Park JE, Bøttig Roa, Dominguez Conde C, Popescu DM, Lavaert M, Kunz DJ, Goh I, Stephenson E, Ragazzini R, Tuck E, Vilbrey-Clark A, Roberts K, Kedlian VR, Ferdinand JR, He X, Webb S, Mauder D, Vandamme N, Mahbubani KT, Polanski K, Mamanova L, Bolt L, Crossland D, de Rita F, Fuller A, Filby A, Maunder D, Vandamme N, Willcox N, Meager A (2013) Anti-AIRE antibodies in Sardinian patients. J Clin Endocrinol Metab 97(4):1120607109. https://doi.org/10.1210/jc.2011-2461

55. Leonard JD, Gilmore DC, Dileepan T, Nawrocka WI, Chao JL, Uibo R, Jäntti K, Hokynar K, Wolff ASB, collaborative Ap, Krohn K, Ranki A, Peterson P, Kisand K, Hayday A (2016) AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166(3):582–595. https://doi.org/10.1016/j.cell.2016.06.024

56. Perry JSA, Lio CJ, Kau AL, Nutsch K, Yang Z, Gordon JI, Fishman D, Kisand K, Hertel C, Rothe M, Remm A, Pihlap M, Alder P, Vilo J, Hunger AS, collaborative Ap, Krohn K, Ranki A, Peterson P, Kisand K, Hayday A (2017) Autoantibodies regulating airway response in chronic bronchitis patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 207(2):291–297. https://doi.org/10.1084/jem.2016.09976

57. Khan IS, Moussch ML, Zhu ML, Conley B, Fasano KJ, Hou Y, Fong L, Su MA, Anderson MS (2014) Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med 211(5):761–768. https://doi.org/10.1084/jem.20131889

58. Su MA, Anderson MS (2019) Pulling RANK on cancer: blocking AIRE-mediated central tolerance to enhance immunotherapy. Cancer Immunol Res 7(6):854–859. https://doi.org/10.1158/2326-6066.cir-18-0912

59. Tazi-Ahnini R, McDonagh AJ, Wengraf DA, Lovewell TR, Vasilopoulos Y, Messenger AG, Cork MJ, Gawkrodger DJ (2008) The autoimmune regulator gene (AIRE) is strongly associated with vitiligo. Br J Dermatol 159(3):591–596. https://doi.org/10.1111/j.1365-2133.2008.08718.x

60. Bérczi B, Gerardcèr G, Farkas N, Hegyi P, Bajor J, Al-Muhsen S, Al-Owain M, Arkwright PD, Anderson MS, (2013) PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity in APECED or Finnish type 1 diabetic patients. Immunogenetics 58(5-6):331–338. https://doi.org/10.1007/s00251-006-0085-3

61. Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Costigan C, McConnell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennell V, Cant AJ, Abinun M, Polak M, Costigan C, Al-Muhsen S, Al-Owain M, Arkwright PD, Costigan C, McGennel...
autoimmunity. J Allergy Clin Immunol 135(6):1578–1588.e1575. https://doi.org/10.1016/j.jaci.2015.01.040

72. Takaba H, Morishita Y, Tomofuji Y, Danks L, Nitta T, Komatsu N, Kodama T, Takayanagi H (2015) Fez2Z orchestrates a thymic program of self-antigen expression for immune tolerance. Cell 163(4):975–987. https://doi.org/10.1016/j.cell.2015.10.013

73. Guo C, Eckler MJ, McKenna WL, McKinsey GL, Rubenstein JL, Chen B (2013) Fez2 expression identifies a multipotent progenitor for neocortical projection neurons, astrocytes, and oligodendrocytes. Neuron 80(5):1167–1174. https://doi.org/10.1016/j.neuron.2013.09.037

74. Hirata T, Suda Y, Nakao K, Narimatsu M, Hirano T, Hibi M (2004) Zinc finger gene fez-like functions in the formation of subplate neurons and thalamocortical axons. Dev Dyn : an official publication of the American Association of Anatomists 230(3):546–556. https://doi.org/10.1002/dvdy.20068

75. Tzartos JS, Stergiou C, Daoussis D, Zisimopoulou P, Andronopoulos AP, Zolota V, Tzartos SJ (2017) Antibodies to aquaporins are frequent in patients with primary Sjögren’s syndrome. Rheumatology (Oxford) 56(12):2114–2122. https://doi.org/10.1093/rheumatology/kex328

76. Clement CC, Moncrieffe H, Lele A, Janow G, Becerra A, Bauli F, Marín-Sánchez A, Álvarez-Sierra D, González O, Lucas-Martin R, St inertmatt LM, Lookstein RM, Anderson MS (2018) Thymic tuft cells promote an IL-4-enriched medulla and shape thymocyte development. Nature 559(7715):627–631. https://doi.org/10.1038/s41586-018-0345-2

77. Van de Velde RL, Friedman NB (1970) Thymic myoid cells and myasthenia gravis. Am J Pathol 59(2):347–368

78. Banabuchi S, Ito T, Park WR, Watanabe N, Shaw JL, Roman E, Arima K, Wang YH, Voo KS, Cao W, Liu YJ (2010) Thymic stromal lymphopoietin-activated plasmacytoid dendritic cells induce the generation of FOXP3+ regulatory T cells in human thymus. J Immunol (Baltimore, Md : 1950) 184(6):2999–3007. https://doi.org/10.4049/jimmunol.0804106

79. Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, Cao W, Liu YJ (2005) Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nat Immunol 6(7):680–688. https://doi.org/10.1038/ni0605

80. Nevo S, Kadouri N, Abramson J (2019) Tuft cells: from the mucosa to the thymus. Immunol Lett 210:1–9. https://doi.org/10.1016/j.imlet.2019.02.003

81. McGinty JW, Ting HA, Billipp TE, Nadjsombati MS, Khan DM, Barrett NA, Liang HE, Matsumoto I, von Moltke J (2020) Tuft-cell-derived leukotrienes drive rapid anti-helminth immunity in the small intestine but are dispensable for anti-protist immunity. Cell Mol Life Sci : CMLS 77(7):1174. https://doi.org/10.1007/s00018-020-02350-w

82. Bourne TC, Malyszko J, Kucharzewski ML (2010) Myeloid cells - implications for a murine in vivo model of type 1 diabetes. J Clin Investig 120(3):693–703.
enhancer establishment. Nat Immunol 18(2):173–183. https://doi.org/10.1038/ni.3646.

127. Polansky JK, Kretschmer K, Freyer J, Flores S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huen H (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663. https://doi.org/10.1002/eji.200838105.

128. Ohkura N, Sakaguchi S (2020) Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases. Cell Res 30(6):465–474. https://doi.org/10.1038/s41590-018-0289-6.

129. Owen DL, Mahmud SA, Sjaastad LE, Williams JB, Spanier JA, Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Olek S, Hamann A, von Boehmer H, Huehn J (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663. https://doi.org/10.1002/eji.200838105.

130. Owen DL, Mahmud SA, Sjaastad LE, Williams JB, Spanier JA, Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Olek S, Hamann A, von Boehmer H, Huehn J (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663. https://doi.org/10.1002/eji.200838105.

131. Owen DL, Mahmud SA, Sjaastad LE, Williams JB, Spanier JA, Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Olek S, Hamann A, von Boehmer H, Huehn J (2008) DNA methylation controls Foxp3 gene expression. Eur J Immunol 38(6):1654–1663. https://doi.org/10.1002/eji.200838105.

132. Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, Douek DC, Patel DD, Haynes BF (2000) Leukemia inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus increases with age and is associated with thymic atrophy. J Immunol (Baltimore, Md : 1960) 150(4):2180–2187. https://doi.org/10.4049/jimmunol.164.2.1810.

133. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. J Clin Invest 106(12):R75. https://doi.org/10.1172/jci111144.

134. Barzaghi F, Amaya Hernandez LC, Neven B, Ricci S, Kucuk ZY, Blessing JJ, Nadeni Z, Satter MA, Ulloa ER, Scherbera A, Roppelt A, Worth A, Silva J, Lloret ML, Bredius RG, Kał A, Pinsk V, Ballauf A, Haerynck F, Bordon V, Dhooge C, Garcia-D, Neth O, Molinos-Quintana A, Valverde-Fernandez J, Broides A, Bhatia M, Khlevner J, Richmond Padilla EJ, Martino S, Montin RK, Sauer MG, Yesilipek A, Kim M, Yilmaz-Demirdag Y, Forster R (2004) Thymic T cell development and progenitor long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study. J Allergy Clin Immunol 114(1):1036–1049.e1035. https://doi.org/10.1016/j.jaci.2007.10.041.

135. Cepika AM, Sato Y, Liu JM, Uyeda MJ, Bacchetta R, Roncarolo MG (2018) Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency. J Allergy Clin Immunol 142(6):1679–1695. https://doi.org/10.1016/j.jaci.2018.10.026.

136. Ohkura N, Yasumizu Y, Kitagawa Y, Tanaka A, Nakamura Y, Motoooka D, Nakamura S, Okada Y, Sakaguchi S (2020) Regulatory T cell-specific epigenomic region variants are a key determinant of susceptibility to common autoimmune diseases. Immunity 52(6):1119–1132.e1114. https://doi.org/10.1016/j.immuni.2020.04.006.

137. Costa-Carvalho BT, de Moraes-Pinto MI, de Almeida LC, de Seixas Alves MT, Maia RP, de Souza RL, Barreto M, Lourenço L, Vicente AM, Coutinho A, Carneiro-Sampaio M (2008) A remarkable depletion of both naïve CD4+ and CD8+ with high proportion of memory T cells in an IPEX infant with a FOXP3 mutation in the forkhead domain. Scand J Immunol 68(1):85–91. https://doi.org/10.1111/j.1365-3083.2008.02055.x.

138. Liston A, Gray DHD, Lesage S, Fletcher AL, Wilson J, Webster KE, Scott HS, Boyd RL, Peltonen L, Goodnow CC (2004) Gene dosage-limiting role of AIRE in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med 200(8):1015–1026. https://doi.org/10.1084/jem.20040581.

139. Guerder S, Hassel C, Carrier A (2019) Thymus-specific serine protease, a protease that shapes the CD4 T cell repertoire. Immuno Gen 71(3):223–232. https://doi.org/10.1007/s00251-018-1078-y.

140. Liu H, Jain R, Guan J, Vuong V, Ishido S, La Gruta NL, Gray DH, Villadangos JA, Minter JD (2016) Ubiquitin ligase MARCH 8 cooperates with CD38 to control surface MHC II expression in thymic epithelium and CD4 T cell selection. J Exp Med 213(9):1695–1703. https://doi.org/10.1084/jem.20160312.

141. von Rohrscheidt J, Petrozzietti E, Nedjic J, Federle C, Krzyzak L, Ploegh HL, Ishido S, Steinkasserer A, Klein L (2016) Thymic CD4 T cell selection requires attenuation of March8-mediated MHCII turnover in cortical epithelial cells through CD83. J Exp Med 213(9):1685–1694. https://doi.org/10.1084/jem.20160316.

142. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426(6965):454–460. https://doi.org/10.1038/nature02119.

143. Verhagen J, Genolet R, Britton GJ, Stevenson BJ, Sabatos-Peyton CA, Dyson J, Luersch IF, Wraith DC (2013) CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc Natl Acad Sci U S A 110(3):E221–E230. https://doi.org/10.1073/pnas.1208573110.

144. Yamaguchi T, Kishi A, Osaki M, Morikawa H, Prieto-Martin P, Wang K, Saito T, Sakaguchi S (2013) Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc Natl Acad Sci U S A 110(23):E2116–E2125. https://doi.org/10.1073/pnas.1307185110.

145. Misslitz A, Pabst O, Hintzen G, Ohl L, Kremmer E, Petrie HT, Förster R (2004) Thymic T cell development and progenitor localization depend on CCR7. J Exp Med 200(4):481–491. https://doi.org/10.1084/jem.20040383.

146. Ueno T, Hara K, Willis MS, Malin MA, Hopken UE, Gray DH, Matsushima K, Lipp M, Springer TA, Boyd RL, Yoshie O, Takahama Y (2002) Role for CCR7 ligands in the emigration of newly generated T lymphocytes from the neonatal thymus. Immunity 16(2):205–218.

147. Kurube H, Liu C, Ueno T, Saito F, Ohigashi I, Seach N, Arakaki R, Hayashi Y, Kitagawa T, Lipp M, Boyd RL, Takahama Y (2006) CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance. Immunity 24(2):165–177. https://doi.org/10.1016/j.immuni.2005.12.011.

148. Nitta T, Kochi Y, Muro R, Tomofuji Y, Okamura T, Murata S, Suzuki H, Sumida T, Yamamoto K, Takayanagi H (2017) Human thymoproteasome variations influence CD8 T cell selection. Sci}
149. Viret C, Leung-Thung-Long S, Serre L, Lamare C, Vignali DA, Malissen B, Carrier A, Guerder S (2011) Thymus-specific serine protease controls autoreactive CD4 T cell development and autoimmunity in mice. J Clin Invest 121(5):1810–1821. https://doi.org/10.1172/JCI43314

150. Schuster C, Gerold KD, Schober K, Probst L, Boemer K, Kim MJ, Ruckdeschel A, Serwold T, Kissler S (2015) The autoimmunity-associated gene CLEC16A modulates thymic epithelial cell autophagy and alters T cell selection. Immunity 42(5):942–952. https://doi.org/10.1016/j.immuni.2015.04.011

151. Hsu LY, Tan YY, Xiao Z, Malissen M, Weiss A (2009) A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmunity reactivation. J Exp Med 206(11):2527–2541. https://doi.org/10.1084/jem.20082902

152. Chan AY, Punwani D, Kadlecek TA, Cowan MJ, Olson JL, Yin C, Pei XY, Shen H, Gao YN, Sun XY, Wang W, Ge Q, Zhang Y (2018) Th1 biased progressive autoimmunity in aged Aire-deficient mice accelerated thymic epithelial cell senescence. Aging Dis 10(3):497–509. https://doi.org/10.14336/ad.2018.0608

153. Flores KG, Li J, Hale LP (2001) B cells in epithelial and perivascular compartments of human adult thymus. Hum Pathol 32(9):926–934. https://doi.org/10.1016/S0046-8177(01)00611-3

154. Zhang J, Wang Y, Aili A, Sun X, Pang X, Ge Q, Zhang Y, Jin R (2019) Geranylgeranylation regulates thymocyte egress. J Exp Med 215(12):2984–2993. https://doi.org/10.1084/jem.20151132

155. Shi H, Liu C, Tan H, Li Y, Nguyen TM, Dhungana Y, Guy C, Vogel P, Neale G, Rankin S, Feng Y, Peng J, Tao W, Chi H (2018) Hippo kinases Mst1 and Mst2 sense and amplify IL-2RSTAT5 signaling in regulatory T cells to establish stable regulatory activity. Immunity 49(5):899–914.e896. https://doi.org/10.1016/j.immuni.2018.10.010

156. Malik T, Bohlander-Willeke AL, Rickemann P, Nitschke P, Rieux-Laucat F, Lutz P, Picard C, Mahlaoui N, Fischer A, de Saint Basile G (2012) MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119(15):3458–3468. https://doi.org/10.1182/blood-2011-09-378364

157. Schipp C, Schlütermann D, Hönscheid A, Nabhani S, Höll J, Oommen PT, Ginzel S, Fleckenstein B, Stork B, Borkhardt A, Stepensky P, Fischer U (2018) EBV negative lymphoma and autoimmune lymphoproliferative syndrome like phenotype extend the clinical spectrum of primary immunodeficiency caused by STK4 deficiency. Front Immunol 9:2400. https://doi.org/10.3389/fimmu.2018.02400

158. Yagi H, Matsumoto M, Nakamura M, Makino S, Suzuki R, Harada M, Itoh T (1996) Defect of thymocyte emigration in a T cell deficiency strain (CTS) of the mouse. J Immunol (Baltimore, Md : 1950) 150(8):3412–3419

159. Hilgers NE, Verschueren JJ (2016) Myasthenia gravis: subgroup classifications - authors' reply. Lancet Neurology 15(4):357–358. https://doi.org/10.1016/s1474-4422(16)00035-1

160. Chuang WY, Ströbel P, Bohlender-Willke AL, Rickemann P, Nix W, Schalke B, Gold R, Kiefer R, Klinker E, Opitz A, Inoue H, Saruhan-Direskeneli G, Bugert P, Wilcox N, Marx A (2014) Late-onset myasthenia gravis - CTLA4(low) geneotype association and low-for-age thymic output of naive T cells. Clin Immunol 148(2):252–259. https://doi.org/10.1016/j.clim.2014.06.005

161. Zachariah MA, Cyster JG (2010) Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science (New York, N.Y) 328(5982):1129–1135. https://doi.org/10.1126/science.1188222

162. Resop RS, Douaisi M, Craft J, Jachimowski LC, Blom B, Uittenbogaart CH (2016) Sphingosine-1-phosphate/sphingosine-1-phosphate receptor 1 signaling is required for migration of naïve human T cells from the thymus to the periphery. J Allergy Clin Immunol 138(2):551–557.e558. https://doi.org/10.1016/j.jaci.2015.12.1339

163. James KD, Cosway EJ, Lucas B, White AJ, Parnell SM, Carvalho-Gaspar M, Tumanov AV, Anderson G, Jenkinson WE (2018) Endothelial cells act as gatekeepers for LbetaR-dependent thymocyte emigration. J Exp Med 215(2):2984–2993. https://doi.org/10.1084/jem.20181345

164. Dang TS, Willet JD, Griffin HR, Morgan NV, O’Boyle A, Arkwright PD, Hughes SM, Abinun M, Tee LJ, Barge D, Engelhardt KR, Jackson M, Cant AJ, Maher ER, Koref MS, Reynard NL, Ali S, Hambleton S (2016) Defective leukocyte adhesion and chemotaxis contributes to combined immunodeficiency in humans with autosomal recessive MST1 Deficiency. J Clin Immunol 36(2):117–122. https://doi.org/10.1007/s10875-016-0232-2

165. Naik S, Lee JK, Zhou X, Zhang R, O’Byrne SE, Willcox N, Ozgul K, Tezcan I, Sanal O (2015) STK4 (MST1) deficiency in two siblings with autoimmune cytopenias: a novel mutation. Clin Immunol (Orlando, Fla) 161(2):316–323. https://doi.org/10.1016/j.clim.2015.06.010

166. Zachariah MA, Cyster JG (2010) Neural crest-derived pericytes promote egress of mature thymocytes at the corticomedullary junction. Science (New York, N.Y) 328(5982):1129–1135. https://doi.org/10.1126/science.1188222
J Autoimmun 52:122–129. https://doi.org/10.1016/j.jaut.2013.12.006

176. Chuang WY, Strobel P, Gold R, Nix W, Schakle B, Kiefer R, Opitz A, Klinker E, Müller-Hermelink HK, Marx A (2005) A CTLA4-high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 58(4):644–648. https://doi.org/10.1002/ana.20577

177. Gregersen PK, Kosoy R, Lee AT, Lamb J, Sussman J, McKeel D, Simpford C, Pirskani-Matell R, Piehl F, Pan-Hammarstom Q, Verschuuren JJ, Titulaer MJ, Niks EH, Marx A, Strobel P, Tackenberg B, Putz M, Manniola AH, Elsais A, Lorentzen AR, Owe JF, Viken MK, Marx A, Pfister F, Schalk B, Saruhan-Direskeneli G, Melms A, Romi F, Hong Y, Skeie GO (2018) Myasthenia gravis and infectious disease. J Neurol 265(6):1251–1258. https://doi.org/10.1007/s00415-018-8751-9

178. Cron MA, Maillard S, Villegas J, Truffault F, Sudres M, Dragin N, Berrith-Aknin S, Le Panse R (2018) Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci 1412(1):137–145. https://doi.org/10.1111/nyas.13519

179. Wekerle H, Ketelsen UP (1977) Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet (London, England) 1(8013):678–680. https://doi.org/10.1016/s0140-6736(77)92118-3

180. Wilcock N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyan P, Dasgupta B, Morgan BP, Vincent A (2008) Autoimmunizing mechanisms in thymus and thymus. Ann N Y Acad Sci 1132:163–173. https://doi.org/10.1196/annals.1405.021

181. Vincent A, Scadding GK, Thomas HC, Newsom-Davis J (1978) In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet (London, England) 1(8059):305–307

182. Sims GP, Shiono H, Wilcock N, Stott DI (2001) Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol (Baltimore, Md.: 1950) 167(4):1935–1944. https://doi.org/10.4049/jimmunol.167.4.1935

183. Weirnberg CB, Hall ZW (1979) Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci U S A 76(1):504–508. https://doi.org/10.1073/pnas.76.1.504

184. Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK (1986) Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Archiv B: Cell Pathology including Molecular Pathology 52(3):237–257

185. Roxanis I, Mickel K, McConville J, Newsom-Davis J, Wilcock N (2002) Thymic myoid cells and germinal center formation in myasthenia gravis: possible roles in pathogenesis. J Neuroimmunol 125(1-2):185–197

186. Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrith-Aknin S, Scavallari F, Cannelas A, Morgan BP, Vincent A, Wilcock N (2007) Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 171(3):893–905. https://doi.org/10.2353/ajpath.2007.070240

187. Safar D, Aimé C, Cohen-Kaminsky S, Berrith-Aknin S (1991) Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 35(1-3):101–110. https://doi.org/10.1016/0165-2478(91)90165-4

188. Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tackelsen K, Berrith-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440. https://doi.org/10.1182/blood-2005-06-2383

189. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tackelsen K, Berrith-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440. https://doi.org/10.1182/blood-2005-06-2383

190. Safar D, Aimé C, Cohen-Kaminsky S, Berrith-Aknin S (1991) Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 35(1-3):101–110. https://doi.org/10.1016/0165-2478(91)90165-4

191. Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tackelsen K, Berrith-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440. https://doi.org/10.1182/blood-2005-06-2383

192. Weinberg CB, Hall ZW (1979) Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc Natl Acad Sci U S A 76(1):504–508. https://doi.org/10.1073/pnas.76.1.504

193. Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK (1986) Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Archiv B: Cell Pathology including Molecular Pathology 52(3):237–257

194. Roxanis I, Mickel K, McConville J, Newsom-Davis J, Wilcock N (2002) Thymic myoid cells and germinal center formation in myasthenia gravis: possible roles in pathogenesis. J Neuroimmunol 125(1-2):185–197

195. Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrith-Aknin S, Scavallari F, Cannelas A, Morgan BP, Vincent A, Wilcock N (2007) Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 171(3):893–905. https://doi.org/10.2353/ajpath.2007.070240

196. Safar D, Aimé C, Cohen-Kaminsky S, Berrith-Aknin S (1991) Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 35(1-3):101–110. https://doi.org/10.1016/0165-2478(91)90165-4

197. Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tackelsen K, Berrith-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440. https://doi.org/10.1182/blood-2005-06-2383

198. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Meraouna A, Cizeron-Clairac G, Panse RL, Bismuth J, Truffault F, Tackelsen K, Berrith-Aknin S (2006) The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 108(2):432–440. https://doi.org/10.1182/blood-2005-06-2383
Silevstari N J, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR (2019) Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. https://doi.org/10.1016/s1474-4422(18)30392-2

200. Hohlfeld R, Wekerle H (2008) Reflections on the “intrathymic pathogenesis” of myasthenia gravis. J Neuroimmunol 201-202: 21–27. https://doi.org/10.1016/j.jneuroim.2008.05.020

201. Melms A, Malcherek G, Gern U, Wiethölter H, Müller CA, Hohlfeld R, Wekerle H (2008) Reflections on the “intrathymic pathogenesis” of myasthenia gravis. J Neuroimmunol 201-202: 21–27. https://doi.org/10.1016/j.jneuroim.2008.05.020

205. Bornemann A, Kirchner T (1998) Thymic myoid cell turnover in healthy subjects and myasthenia gravis patients. Neurology 432(4):357–361. https://doi.org/10.1007/s004280050178

206. Balandina A, Lécart S, Dartevelle P, Saoudi A, Berrih-Aknin S (2005) Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105(2):735–741. https://doi.org/10.1182/blood-2003-11-3900

207. Truffault F, Nazzal D, Verchot E, Grizot O, Jouffre OP, Robey EA, van Meerwijk JP, Romagnoli P (2015) Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors. Nat Immunol 16(6):628–634. https://doi.org/10.1038/ni.3150

208. Corigliani C, Marolda R, Franz S, Capello C, Giardina C, Motta T, Baggi F, Bernasconi P, Mantegazza R, Cavalcante P (2014) Intrinsic immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. J Autoimmun 52:74–89. https://doi.org/10.1016/j.jaut.2013.12.013

209. Fujii Y, Monden Y, Hashimoto J, Nakahara K, Kawashima Y (1985) Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis. Clin Immunol Immunopathol 34(1):141–146. https://doi.org/10.1016/0090-1229(85)90018-2

210. Strobel P, Hartmann E, Rosenwald A, Kalla J, Ott G, Friedel G, Schalke B, Kasahara M, Tomaru U, Marx A (2014) Corticomedullary differentiation and maturational arrest in thymomas. Histopathology 64(4):557–566. https://doi.org/10.1111/his.12279

211. Willecox N, Schluep M, Ritter MA, Schuurman HJ, Newsom-Davis J, Christenson B (1987) Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 127(3):447–460.

212. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willecox N (2001) Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 50(1):64–72

213. Nitta H, Mihara K, Sakai A, Kimura A (2010) Expansion of CD8+ perforin+ effector memory T cells in the bone marrow of patients with thymoma-associated pure red cell aplasia. Br J Haematol 150(6):712–715. https://doi.org/10.1111/j.1365-2414.2010.08273.x

214. Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowly R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MD, Sethi G, Lu C, Ryan M, Su X, Chemiack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Fujiimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Okmen-Polar Y, Badve S, Rajan A, Strobel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrle PJ (2018) The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33(2):244–258.e210. https://doi.org/10.1016/j.ccell.2018.01.003

215. Strobel P, Murumagi A, Klein A, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A (2007) Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 211(5):563–571. https://doi.org/10.1002/path.2141

216. Ströbel P, Preischofen T, Helmreich M, Menioudakis G, Lewin SR, Rudiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Eleti O, Semik M, Muller-Hermelink HK, Marx A (2002) Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+ T cells in thymomas. Blood 100(1):159–166

217. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2000) Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease. Blood 96(12):3872–3879

218. Ströbel P, Reinhold T, Helmreich M, Müller-Hermelink HK, Marx A (2003) Pathomechanisms of paraneoplastic myasthenia gravis. Clin Dev Immunol 10(1):7–12. https://doi.org/10.1080/10446670310001598528

219. Nagvarkar N, Woody AM, Moss P, Roxanis I, Curnow J, Beesons D, Pantic N, Newsom-Davis J, Vincent A, Willcox N (1998) A pathogenetic role for the thymoma in myasthenia gravis. Autoimmunization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 101(10):2268–2277. https://doi.org/10.1172/jci2068

220. Shiorno H, Wong YL, Matthews I, Liu JL, Zhang W, Sims G, Meager A, Beesons D, Vincent A, Willcox N (2003) Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggest autoimmunization in the tumor. Int Immunol 15(8):903–913. https://doi.org/10.1093/intimm/dxq088

221. Liu Y, Zhang H, Zhang P, Meng F, Chen Y, Wang Y, Yao Y, Qi B (2014) Autoimmune regulator expression in thymomas with or without autoimmune disease. Immunol Lett 161(1):50–56. https://doi.org/10.1016/j.imlet.2014.04.008

222. Ramsey C, Hässler S, Marits P, Kämpe O, Surh CD, Peltonen L, Winquist O (2006) Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. Eur J Immunol 36(2):305–317. https://doi.org/10.1002/eji.200535240

223. Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Müller-Hermelink HK, Peterson P, Marx A (2008) Common cellular and
diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci 1132:143–156. https://doi.org/10.1196/annals.1405.018

225. Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, Sillanpaa N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A (2004) Selective loss of regulatory T cells in thymomas. Ann Neurol 56(6):901–904. https://doi.org/10.1002/ana.20340

226. Zettl A, Ströbel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein a, Semik M, Müller-Hermelink HK, Marx A (2000) Recurrent genetic aberrations in thymoma HK, Marx A (2000) Recurrent genetic aberrations in thymoma HK, Marx A 43(5-6):413–427. https://doi.org/10.3109/08916930003555935

227. Zhao C, Rajan A (2019) Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum (Hong Kong, China) 3:35. https://doi.org/10.21037/med.2019.08.02

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.